A Phase II, Randomized, Double-Blind Study of the Use of Rucaparib Versus Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

There is a convincing rationale to consider PARP inhibition therapy in endometrial cancer. Similar to their use in other malignancies, targeting DNA repair mechanisms can be effective in endometrial cancer. However, the pathway to DNA repair deficiencies may be different. We hypothesized that the use of maintenance rucaparib will have therapeutic benefits for patients with metastatic and recurrent endometrial cancer.